The next focusIR Investor Webinar takes places on 14th May with guest speakers from WS Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksDestiny Pharma. Share News (DEST)

Share Price Information for Destiny Pharma. (DEST)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 17.00
Bid: 16.50
Ask: 17.50
Change: -0.50 (-2.86%)
Spread: 1.00 (6.061%)
Open: 17.50
High: 17.50
Low: 17.00
Prev. Close: 17.50
DEST Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

TRADING UPDATES: Dianomi swings to loss; Epwin revenue up

Wed, 20th Sep 2023 14:27

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Wednesday and not separately reported by Alliance News:

----------

Epwin Group PLC - Solihull, England-based building products manufacturer - Revenue in six months to June 30 up 1.1% to GBP180.0 million from GBP178.0 million. Pretax profit flat at GBP7.9 million. Interim dividend per share rises 5.3% to 2.0 pence from 1.9p a year prior. "Q3 trading to date has been encouraging with profitability ahead of 2022," Epwin adds. It expects to report annual results in line with market expectations. Underlying operating profit expectations stand at GBP24.0 million, which would represent a 12% rise from GBP21.5 million in 2022.

----------

Dianomi PLC - London-based digital advertising platform - Revenue in half-year ended June 30 drops 18% to GBP14.8 million from GBP18.0 million, amid "decline in traffic volumes across the group's direct publisher inventory". Swings to pretax loss of GBP2.1 million from profit of GBP897,000 a year earlier. "We are mindful of an environment that continues to be challenging and the need to adapt. The group's operational cost base has been streamlined and optimised following the restructuring of the group's global management and sales teams, resulting in an annualised cost reduction of GBP1 million. However, in spite of a difficult backdrop, I am pleased to report that Dianomi continues to attract new clients and now counts all 10 of the top 10 US asset managers as clients," Chief Executive Rupert Hodson says. Dianomi expects a profitable second-half. In addition, the firm explained it has agreed a contract amendment with "one of its largest and longest standing publisher partners". While bullish that the amendment is good news in the long-term, Dianomi noted the arrangement hurt its adjusted earnings before, interest, tax, depreciation and amortisation for the six months of 2023. "There will be a short-term impact on cash of GBP500,000 in the current financial year which will unwind during 2024," the firm says. Dianomi says minimum traffic levels were not met, meaning it was overpaid by the publisher to tune of USD1 million. Dianomi adds: "Following discussions, the company and the publisher have entered into an amendment to the agreement whereby Dianomi has agreed not to recoup the overpayment, in return for which the publisher will provide Dianomi with an enhanced revenue share as from 1 July 2023 and, in addition to its existing permanent ad units, will provide Dianomi with additional premium ad inventory, including a new in-article unit."

----------

Ten Entertainment Group PLC - ten-pin bowling operator - Total sales in half-year ended July 2 improve 3.3% on-year to GBP65.3 million from GBP63.2 million a year earlier. Pretax profit, however, falls by a quarter to GBP15.8 million from GBP21.0 million. The prior year's bottom line got a GBP4.4 million boost from a claim for reduced rate of VAT on bowling. Ten Entertainment adds: "An ongoing focus on refurbishment, customer service and digital communications gives us confidence that we can continue to deliver like-for-like sales growth from the existing estate through addition of new activities and focus on the core entertainment experience. Cost inflation remains manageable, and we expect a slightly lower than the UK headline rate as a function of our long-term supplier strategy." The firm adds year-to-date like-for-like sales are 4.7% higher.

----------

DP Aircraft I Ltd - Guernsey-based aircraft leasing company - Lease rental in six months to June 30 falls 43% to USD4.3 million from USD7.6 million a year earlier. DP Aircraft swings to a pretax loss of USD4.1 million from profit of USD3.0 million. "There has been a continued improvement in the global aviation market following the challenges resulting from the effects of the Covid-19 pandemic. Recent sentiment on airline and related stocks has been more optimistic. The Ukraine war has not had as significant an impact on the industry as expected. With Covid-19 restrictions in China being lifted there is cause for some optimism in tourism numbers from that market in Thailand going forward," DP Aircraft says.

----------

Destiny Pharma PLC - Brighton, England-based clinical-stage biotechnology company focused on preventing life-threatening infections - Reports licence fee income of GBP831,552 in first half ended June 30, against none a year earlier. Pretax loss narrows to GBP3.1 million from GBP3.8 million. CEO Chris Tovey says: "The partnering of NTCD-M3 and the associated fundraising during the period demonstrate our ability to generate significant value from our assets, and have positioned the company for success as we advance the Phase 3 development programme for M3 and intensify our partnering activities for our lead asset, XF-73 nasal. The company is now funded through to Q1 2025, allowing us to deliver our planned activities."

----------

Ethernity Networks Ltd - supplier of data processing semiconductor technology for networking appliances - Revenue in first half ended June 30 surges 98% to USD1.4 million from USD704,853. Pretax loss, however, widens to USD3.6 million from USD3.5 million. Reports financing income of just GBP322,814, down from GBP1.2 million a year earlier. Ethernity adds: "The company is targeting the achievement of positive cash flow generation from operations during the second half of 2023 by continuing to fulfil customers' orders and from anticipated revenue from new contracts, in combination with a reduction in expenses."

----------

By Eric Cunha, Alliance News news editor

Comments and questions to newsroom@alliancenews.com

Copyright 2023 Alliance News Ltd. All Rights Reserved.

More News
27 May 2021 16:06

UK shareholder meetings calendar - next 7 days

UK shareholder meetings calendar - next 7 days

Read more
14 Apr 2021 12:04

TRADING UPDATES: Quixant swings to 2020 loss but recommends dividend

TRADING UPDATES: Quixant swings to 2020 loss but recommends dividend

Read more
7 Apr 2021 15:58

UK earnings, trading statements calendar - next 7 days

UK earnings, trading statements calendar - next 7 days

Read more
29 Mar 2021 09:59

AIM WINNERS & LOSERS: Destiny Pharma jumps on positive nasal gel study

AIM WINNERS & LOSERS: Destiny Pharma jumps on positive nasal gel study

Read more
29 Mar 2021 09:02

Destiny Pharma jumps as infection-fighting nasal gel shows promise

Destiny Pharma jumps as infection-fighting nasal gel shows promise

Read more
15 Mar 2021 21:44

TRADING UPDATES: Arix backs buyback; 88 Energy notes share price surge

TRADING UPDATES: Arix backs buyback; 88 Energy notes share price surge

Read more
10 Mar 2021 20:22

IN BRIEF: Destiny Pharma CSO joins UK Covid-19 research taskforce

IN BRIEF: Destiny Pharma CSO joins UK Covid-19 research taskforce

Read more
3 Feb 2021 11:09

IN BRIEF: Destiny Pharma Secures Brazilian Patent For XF-73 Nasal Gel

IN BRIEF: Destiny Pharma Secures Brazilian Patent For XF-73 Nasal Gel

Read more
2 Feb 2021 14:34

IN BRIEF: Destiny Pharma Adds Mark Wilcox To Scientific Advisory Board

IN BRIEF: Destiny Pharma Adds Mark Wilcox To Scientific Advisory Board

Read more
6 Jan 2021 14:27

UK EXECUTIVE CHANGE SUMMARY: Martin Gilbert Joins River & Mercantile

UK EXECUTIVE CHANGE SUMMARY: Martin Gilbert Joins River & Mercantile

Read more
5 Jan 2021 21:15

IN BRIEF: Destiny Pharma Completes Recruitment For XF-73 Gel Trial

IN BRIEF: Destiny Pharma Completes Recruitment For XF-73 Gel Trial

Read more
5 Jan 2021 11:21

Destiny Pharma meets recruitment deadline for XF-73 trial

(Sharecast News) - Clinical-stage biotechnology company Destiny Pharma announced on Tuesday that its XF-73 phase 2b clinical trial was fully recruited by 31 December, meeting the target timeline set for the programme.

Read more
22 Dec 2020 18:06

UK TRADING UPDATE SUMMARY: Lekoil Fires Back At Shareholder Metallon

UK TRADING UPDATE SUMMARY: Lekoil Fires Back At Shareholder Metallon

Read more
25 Nov 2020 18:00

UK TRADING UPDATE SUMMARY: SourceBio Tips Jump In Virus Testing Demand

UK TRADING UPDATE SUMMARY: SourceBio Tips Jump In Virus Testing Demand

Read more
9 Nov 2020 17:15

Destiny Pharma Set For GBP11.5 Million Raise To Buy NTCD-M3

Destiny Pharma Set For GBP11.5 Million Raise To Buy NTCD-M3

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.